Bart Jan Kullberg

Radboud University Nijmegen — Netherlands

Medicine · Health Sciences

109h-index53.8kcitations472works15.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antifungal resistance and susceptibility(190), Fungal Infections and Studies(116), Immune Response and Inflammation(87), Vector-borne infectious diseases(41), Inflammasome and immune disorders(32)

Publications472 total

Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study
Open Forum Infectious Diseases·2025· 2 citedOpen Access
Diagnostic validation of novel Borrelia antigens discovered by whole-proteome microarray: Advancing early detection and test of cure for Lyme disease
Cell Reports Medicine·2025· 1 citedOpen Access
EXTENDED SURGICAL ANTIBIOTIC PROPHYLAXIS NOT SUPERIOR TO A SINGLE DOSE IN TOTAL HIP AND KNEE REVISION ARTHROPLASTY: A MULTICENTRE OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
Orthopaedic Proceedings·2024
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials
Critical Care·2024· 13 citedOpen Access
Treatment Outcomes Among Patients With a Positive<i>Candida</i>Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study
Clinical Infectious Diseases·2024· 6 citedOpen Access
Impact de la pandémie de COVID-19 sur l'étude ReSTORE : essai de phase 3 de la rezafungine et de la caspofungine pour traiter les candidémies et candidoses invasives
Médecine et Maladies Infectieuses Formation·2024
Towards personalized medicine: a scoping review of immunotherapy in sepsis
Critical Care·2024· 39 citedOpen Access
A comprehensive genetic map of cytokine responses in Lyme borreliosis
Nature Communications·2024· 11 citedOpen Access
Genome-wide analyses in Lyme borreliosis: identification of a genetic variant associated with disease susceptibility and its immunological implications
BMC Infectious Diseases·2024· 8 citedOpen Access
Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM
Intensive Care Medicine·2024· 137 citedOpen Access
Evaluation and 1-year follow-up of patients presenting at a Lyme borreliosis expertise centre: a prospective cohort study with validated questionnaires
European Journal of Clinical Microbiology & Infectious Diseases·2024· 2 citedOpen Access
P29 Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with candidaemia and/or invasive candidiasis: integrated analysis of pooled Phase 2 and Phase 3 data
JAC-Antimicrobial Resistance·2024· 1 citedOpen Access
Déterminants des symptômes persistants après traitement de la borréliose de Lyme : une étude de cohorte observationnelle prospective
Mains Libres·2024
Diagnostic Validation of Novel Borrelia Antigens Discovered by Whole Proteome Microarray: New Horizons for Early Diagnosis and Test-of-Cure of Lyme Disease
SSRN Electronic Journal·2024Open Access
Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study
EBioMedicine·2023· 34 citedOpen Access
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials
The Lancet Infectious Diseases·2023· 60 citedOpen Access
P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
JAC-Antimicrobial Resistance·2023· 1 citedOpen Access
Classical Borrelia Serology Does Not Aid in the Diagnosis of Persistent Symptoms Attributed to Lyme Borreliosis: A Retrospective Cohort Study
Life·2023· 1 citedOpen Access
Résultats par pathogènes en baseline et sensibilité dans l'essai de phase 3 ReSTORE de la rezafungine une fois par semaine vs caspofungine une fois par jour chez les patients atteints de candidémies et/ou de candidose invasive.
Médecine et Maladies Infectieuses Formation·2023
Correction to “Prevalence of persistent symptoms after treatment for lyme borreliosis: a prospective observational cohort study”
The Lancet Regional Health - Europe·2023Open Access
page 1 of 24Next →

Frequent Co-authors

Mihai G. Netea(31), J.W.M. van der Meer(13), Leo A. B. Joosten(12), Paul E. Verweij(10), Thierry Calandra(9), Claudio Viscoli(9), Frank L. van de Veerdonk(9), Jos W.M. van der Meer(9), Gosse J. Adema(9), J. Peter Donnelly(8), Olivier Lortholary(8), Matteo Bassetti(8), Maiken Cavling Arendrup(8), Oliver A. Cornely(8), Raoul Herbrecht(7), Andreas H. Groll(7), Gerben Ferwerda(7), Johan Maertens(6), Jacques Billé(6), Elio Castagnola(6)